Tertiary prophylaxis in adults: Is there a rationale?

Haemophilia

Volumn 18, Issue 5, 2012, Pages 722-728

  Gringeri, A ^a   Lambert, T ^b   Street, A ^c   Aledort, L ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b BICÊTRE HOSPITAL   (France)

^c Ronald Sawers Haemophilia Centre   (Australia)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adult; Cost; Haemophilia; Prophylaxis

Indexed keywords

ARTHROPATHY; ARTICLE; BLEEDING; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEMOPHILIA; HUMAN; MENTAL HEALTH; PATIENT AUTONOMY; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REHABILITATION; SOCIAL INTERACTION; SOCIAL PARTICIPATION;

ADULT; BLOOD COAGULATION FACTORS; COHORT STUDIES; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HEMARTHROSIS; HEMOPHILIA A; HUMANS; LONGITUDINAL STUDIES; MALE; TERTIARY HEALTHCARE;

EID: 84865543422     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02843.x     Document Type: Article

References (44)

1. Roosendaal G, Tekoppele JM, Vianen ME, van denBerg HM, Lafeber FP, Bijlsma JW. Articular cartilage is more susceptible to blood induced damage at young than at old age. J Rheumatol 2000; 27: 1740-4.
2. Roosendaal G, Jansen NW, Schutgens R, Lafeber FP. Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment. Haemophilia 2008; 14 (Suppl. 6): 4-10.
3. Darby SC, Kan SW, Spooner RJ et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-25.
4. Plug I, van derBom JG, Peters M et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004; 104: 3494-500.
5. Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65: 129-35.
6. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
7. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
8. Berntorp E. Guidelines on treatment of haemophilia in Sweden. Haemophilia 1998; 4: 421-30.
9. National Hemophilia Foundation. MASAC Recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). [Last accessed on 4 August 2009]. Document #179. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007.
10. Santagostino E, Mannucci PM. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000; 6: 1-10.
11. United Kingdom Haemophilia Centre Doctors Organisation (UKHCDO). Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003; 9: 1-23.
12. Delivery of treatment for haemophilia. Report of a Joint WHO/WFH/ISTH meeting, London 11-12 February 2002. WHO/HGN/ISTH/WG/02.6.
13. Colvin BT, Astermark J, Fischer K et al. Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia 2008; 14: 361-74.
14. Berntorp E, Astermark J, Björkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9 (Suppl. 1): 1-4.
15. Richards M, Altisent C, Batorova A et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? A European survey of practice and outcome data. Haemophilia 2007; 13: 473-9.
16. Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia 2009; 15: 1014-21.
17. Biss TT, Chan AK, Blanchette VS, Iwenofu LN, McLimont M, Carcao MD; Association of Hemophilia Clinic Directors of Canada (AHCDC); Canadian Association of Nurses in Hemophilia Care (CANHC). The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008; 14: 923-30.
18. Donadel-Claeyssens on behalf of the European Network for Haemophilia Management. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006; 12: 124-7.
19. Tagliaferri A, Di Perna C, Rivolta GF. Secondary prophylaxis in adolescent and adult haemophiliacs. Blood Transfus 2008; 6 (Suppl. 2): s17-20.
20. Rocino A, Salerno E, Capasso F et al. Secondary prophylaxis in severe haemophilia A: results in preventing further joint damage. Thromb Haemost 1999; 82 (Suppl.): 610 [Abstract 1923A].
21. Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med 1998; 244: 515-22. [PubMed].
22. Loverin JA, Mensah P, Nokes TJC. Limited prophylaxis in adults with severe hemophilia: a pilot study. Haemophilia 2000; 6: 274-5. [abstract].
23. Saba HI, Tannenbaum B, Morelli G et al. Factor prophylaxis in the management of adult hemophiliacs. Haemophilia 2000; 6: 276-7. [abstract].
24. Schramm W, Royal S, Kroner B et al. for the European haemophilia economic study group. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
25. Fischer K, Van Dijk K, Van den Berg HM. Late prophylaxis for severe hemophilia: effects of prophylaxis started in adulthood. J Thromb Haemost 2005; 3 (Suppl. 1). OR205 [Abstract].
26. Coppola A, Cimino E, Macarone Palmieri N et al. Clinical and pharmacoeconomic impact of secondary prophylaxis in young-adults with severe hemophilia A. J Thromb Haemost 2005; 3 (Suppl. 1): P1428 [Abstract].
27. Tagliaferri A, Rivolta GF, Rossetti G et al. Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs. Thromb Haemost 2006; 96: 542-3.
28. Tagliaferri A, Franchini M, Coppola A et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-51.
29. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic versus on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
30. Valentino LA, Mamonov V, Hellmann A et al. for the Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
31. Miners A. Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A. Haemophilia 2009; 15: 881-7.
32. Lippert B, Berger K, Berntorp E et al. Cost effectiveness of haemophilia treatment: a cross-national assessment. Blood Coagul Fibrinolysis 2005; 16: 477-85.
33. Risebrough N, Oh P, Blanchette V, Curtin J, Hitzler J, Feldman BM. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia 2008; 14: 743-52.
34. Farrugia A, O'Mahony B, Cassar J. Health technology assessment and haemophilia. Haemophilia 2012; 18: 152-7.
35. Aledort LM. Orthopedic outcome studies and cost issues. Semin Thromb Hemost 2003; 29: 55-60.
36. Royal S, Schramm W, Berntorp E et al. for the European haemophilia economics study group. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.
37. Ware JJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) I Conceptual framework and item selection. Med Care 1992; 30: 473.
38. Lindvall K, Von Mackensen S, Berntorp E. Quality of life in adult patients with haemophilia-a single centre experience from Sweden. Haemophilia 2012 [Epub ahead of print]. DOI: 10.1111/j.1365-2516.2012.02765.x.
39. Darby SC, Keeling DM, Spooner RJ et al. UK Haemophilia Centre Doctors' Organisation. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
40. Collins PW, Blanchette VS, Fischer K et al. rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
41. Collins PW, Björkman S, Fischer K et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 8: 269-75.
42. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30 (3 Suppl. 2): 3-6.
43. Pettersson H. Radiographic scores and implications. Semin Hematol 1993; 30 (3 Suppl. 2): 7-9.
44. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 149: 153-9.